EDIGENE INC.

History

Year	Detail
2015	The company Edigene Inc. was established in Beijing, China.
2017	It has Collaborarted with a team of clinical experts and established Gene editing therapy platform.
2019	RNA single-base editing technology LEAPER was first reported in Nature Biotechnology.
2020	The clinical trial application for ET-01, a gene editing therapy research product for the treatment of β-thalassemia, was accepted by the National Medical Products Administration.
2021	ET-01's clinical trial application was approved by the National Medical Products Administration and First patient enrolled in ET-01 Phase I multicenter clinical trial. Hematopoietic stem cell research results presented at ASH.
2022	Signed a strategic cooperation R&D agreement with Haihe Laboratory of Cell Ecology. Entered into a global non-exclusive license agreement with Arbor Biotechnologies. Collaborated with Peking University Cancer Hospital.
2023	Preclinical data of LEAPER 2.0-based in vivo RNA editing therapy in NHP models presented in an oral presentation at the 26th ASGCT Annual Meeting.